Latest From Inivata Ltd.
The Top 5 Market Intel Stories Of 2019: A Mixed Bag Of Hemodialysis, Robotics, Ophthalmology, Femtech And Liquid Biopsy
A look back at Medtech Insight’s five most-read Market Intelligence features of 2019 reveals a diverse mix of interests among our readers – hemodialysis, robotic surgeries, ophthalmic surgical solutions, liquid biopsy and digital technologies that seek to improve women's health.
Cambridge Innovation Capital completes £150m fundraising to give it more firepower to reinforce Cambridge, UK’s pre-eminent status as Europe’s leading life sciences and tech hub.
Inivata has raised $52.6m to support commercialization of its blood test for non-small cell lung cancer (NSCLC) diagnosis.
Liquid biopsy is a rapidly developing noninvasive technology for the early detection of cancer. Multiple companies have entered clinical testing, using mostly blood to detect circulating tumor cells and/or circulating tumor DNA. But urine and even cerebral spinal fluid are promising liquids too. Regardless of the fluid, testing costs a fraction of a traditional, invasive tissue biopsy and offers much quicker results.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Inivata Ltd.
- Senior Management
Clive Morris, CEO
Tim Shannon, CFO
Nitzan Rosenfeld, PhD, CSO
Jamie Platt, PhD, COO
- Contact Info
Phone: 1223 790 880
The Portway Bldg.
Cambridge, CB21 6GS
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.